SCHEMBL6636827

SCHEMBL6636827

CCCCCNCc1c[c]ccc1

nearest known ligand 0.54

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.54
HRH3 Q9Y5N1 1/20 0.54
CYP1A2 P05177 3/20 0.53
CYP2D6 P10635 3/20 0.53
CYP2C19 P33261 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 1/20 0.49
SIGMAR1 Q99720 4/20 0.49
MAOA P21397 1/20 0.47
CHRM2 P08172 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6637837 0.98 CYP1A2 (0.54) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL6634166 0.95 HRH4 (0.47) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL6638323 0.88 MEN1 (0.42) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL2477823 0.80 GAA (0.37) CYP1A2CYP2D6SMN1; SMN2LMNAMAOA
SCHEMBL27549496 0.80 SIGMAR1 (0.61) SIGMAR1MAOACHRM2
Water SCHEMBL28159331 0.79 MAOA (0.77) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL8995481 0.79 HRH4 (0.67) HRH4HRH3CYP1A2CYP2D6CYP2C19
Water SCHEMBL6256324 0.79 MAOA (0.77) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL19692812 0.78 HRH4 (0.61) HRH4HRH3CYP1A2CYP2D6CYP2C19
SCHEMBL538475 0.78 MAOA (0.76) HRH4HRH3CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1165557-B1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS NEUROGEN CORP (US) 2004-09-29 EP claimed
US-6627624-B1 Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, NEUROGEN CORPORATION 2003-09-30 US claimed
EP-1165557-B1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS NEUROGEN CORP (US) 2004-09-29 EP disclosed